Medicine
Oxlumo 94.5 mg/0.5 mL injection
Oxlumo 94.5 mg/0.5 mL injection is a prescription medicine containing Lumasiran for subcutaneous use, marketed by Alnylam Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 2°C to 25°C [36°F to 77°F]. Store OXLUMO in its original container…
Key facts
- Active ingredient (INN)
- Lumasiran
- Brand
- Oxlumo
- Strength
- 94.5 mg/0.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 0.5 mL
- Marketing authorisation holder
- Alnylam Pharmaceuticals
- Manufacturer
- Alnylam Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 2°C to 25°C [36°F to 77°F]. Store OXLUMO in its original container until ready for use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AX18 Lumasiran
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 November 2020
- Identifiers
- RxCUI 2467153, 2467158DailyMed set ID 16985a31-f5e4-4557-9266-fc78d4bc5055NDC 71336-1002Application NDA214103
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / .5 mL in 1 vial, single-use | 71336-1002-1 | Alnylam Pharmaceuticals | 23 November 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Lumasiran is a prescription medicine indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. It is available as injection for subcutaneous use. MedsAcross supplies Lumasiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LumasiranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OXLUMO prescribing information (Alnylam Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Oxlumo: European public assessment report (EPAR) · European Medicines Agency
Need Oxlumo 94.5 mg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.